Curocell

Curocell Total Assets

The Total Assets of Curocell (372320.KQ) as of Oct 27, 2026 is 109.72 B KRW. In the previous year, Total Assets was 72.02 B KRW — a change of 52.34% (higher).

Total Assets

109.72 BKRW

YoY

52.34%

Last updated:

Total Assets of Curocell is 2025 109.72 B KRW. Total Assets of Curocell was 2024 72.02 B KRW. It decreases by 52.34% higher compared to the previous year.

The Curocell Total Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Total Assets
Date
Total Assets
Jan 1, 2021
82.16 B KRW
Jan 1, 2022
87.99 B KRW
Jan 1, 2023
104.97 B KRW
Jan 1, 2024
72.02 B KRW
Jan 1, 2025
109.72 B KRW
The Curocell Total Assets history
YEARTotal AssetsYoY
109.72 BKRW+52.34%
72.02 BKRW-31.39%
104.97 BKRW+19.30%
87.99 BKRW+7.09%
82.16 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Curocell Stock analysis

What does Curocell do? Curocell Inc makes money through the development and commercialization of CAR-T therapy technologies for cancer treatment. The company focuses on novel chimeric antigen receptor (CAR)-T therapies targeting specific cancer antigens, improving medicinal effects, reducing side effects, and automating quality analysis. These products are developed for pharmaceutical companies and healthcare providers seeking advanced cancer treatments. The firm's R&D efforts target the biotechnology sector, specifically oncology applications. Curocell Inc's business model centers on creating innovative CAR-T therapies that address unmet medical needs in cancer care. The company's research and development activities are directed at enhancing the efficacy and safety of CAR-T treatments, which are sold to pharmaceutical firms for further development and distribution. The firm's products are positioned within the biotechnology industry, catering to the growing demand for targeted cancer therapies. The company's revenue streams come from the sale of its developed CAR-T technologies to pharmaceutical partners. These partnerships enable the commercialization of Curocell's innovations in the global oncology market. Curocell Inc operates within the biotechnology sector, specifically focusing on the development of next-generation CAR-T therapies for cancer patients. Curocell is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Curocell stock

Total Assets of Curocell is 109.72 B KRW in 2025.

Total Assets of Curocell changed from 72.02 B KRW to 109.72 B KRW, representing a 52.34% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Total Assets Curocell since 2006 – with annual values, charts, and detailed analysis.

Total assets represent everything a company owns, including cash, inventory, property, and intangible assets. It is a key measure of a company's size and resource base.

Total Assets's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Total Assets's Curocell historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Curocell

All Key Metrics — Curocell